BBOT_KONQUER-101 - Clinical Trial

What is the Purpose of this Study?

This study has two parts. In the first part, researchers will test different doses of the study drug BBO-11818, alone and with other cancer treatments, to find a safe and effective dose. In the second part, more participants with specific types of cancer and KRAS mutations will receive BBO-11818 either by itself or with other medicines. Researchers will study its safety, effectiveness, and side effects.

What is the Condition Being Studied?

This study is for people with advanced non-small cell lung cancer, colorectal cancer, pancreatic cancer, or another solid tumor that has a specific KRAS gene mutation. Researchers are testing new treatments for cancers with these KRAS mutations.

Who Can Participate in the Study?

Participants may be able to join if they are adults with advanced cancer that cannot be removed with surgery or has spread to other parts of the body. They must have measurable tumors, be expected to live at least 12 more weeks, and be willing to complete study visits and procedures. Those with tumors that cannot be treated with curative radiation therapy may also be eligible.

Age Group
Adults

What is Involved?

This study is testing a new drug called BBO-11818 in people with advanced solid tumors. Researchers want to find the safest and most effective dose when the drug is used alone or combined with standard cancer treatments. They will also study its benefits, risks, and side effects in people with cancers that have specific KRAS mutations.

Study Details

Full Title
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects with Advanced KRAS Mutant Cancers
Principal Investigator
Laura Alder, MD
Medical Oncologist
Protocol Number
IRB: PRO00119798
NCT: NCT06917079
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Support Duke Health research or honor a loved one with a tribute gift.
Giving to Duke Health